Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | SCN4A | P35499 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23861677 | 0.89 | SCN9A (0.46) | SCN9AMRGPRX4MEN1ALDH1A1KMT2A | |
| SCHEMBL21800837 | 0.89 | SCN9A (0.40) | S1PR5SCN9AMRGPRX4MEN1ALDH1A1 | |
| SCHEMBL18571141 | 0.88 | BRD4 (0.41) | SCN9ATRPM8BRD4 | |
| SCHEMBL18571134 | 0.86 | SCN7A (0.44) | RAB9AS1PR5SCN9AMRGPRX4MEN1 | |
| SCHEMBL21800830 | 0.86 | SCN7A (0.44) | RAB9AS1PR5SCN9AMRGPRX4MEN1 | |
| SCHEMBL18556179 | 0.86 | SCN7A (0.44) | RAB9AS1PR5SCN9AMRGPRX4MEN1 | |
| SCHEMBL23861668 | 0.86 | SCN7A (0.44) | RAB9AS1PR5SCN9AMRGPRX4MEN1 | |
| SCHEMBL18556036 | 0.85 | MEN1 (0.46) | RAB9AS1PR5SCN9AMRGPRX4MEN1 | |
| SCHEMBL30261516 | 0.80 | MRGPRX4 (0.60) | RAB9ASCN9AMRGPRX4MEN1KMT2A | |
| SCHEMBL23861690 | 0.79 | SCN9A (0.45) | SCN9ASCN4ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220055977-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-02-24 | — | — | US | disclosed |
| US-11130726-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-20200087239-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-03-19 | — | — | US | disclosed |
| EP-3341353-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2018-07-04 | — | — | EP | disclosed |
| WO-2017035271-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130726-B2 | Therapeutic compounds and methods of use thereof | RDX, C3AR1, LPXN | RAB9A 545/4885S1PR5 1322/4885SCN9A 1789/4885 |
| US-20200087239-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C3AR1, LPXN | RAB9A 545/4885S1PR5 1322/4885SCN9A 1789/4885 |
| US-20220055977-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | REN, RDX, MC2R | RAB9A 752/4885S1PR5 495/4885SCN9A 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.